See today's BioWorld MedTech
To read the full story, subscribe or sign in.

FDA not interested in extending comment period for LDT draft rule

Oct. 31, 2023
By Mark McCarty
The U.S. FDA’s draft rulemaking for regulation of lab-developed tests (LDTs) came with a conspicuously short comment period of 60 days, but the agency is unresponsive to requests to add another 30 days to the comment period.
BioWorld MedTech Regulatory Diagnostics FDA